Cargando…

Sex and Gender Disparities in Melanoma

Worldwide, the total incidence of cutaneous melanoma is higher in men than in women, with some differences related to ethnicity and age and, above all, sex and gender. Differences exist in respect to the anatomic localization of melanoma, in that it is more frequent on the trunk in men and on the lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellenghi, Maria, Puglisi, Rossella, Pontecorvi, Giada, De Feo, Alessandra, Carè, Alessandra, Mattia, Gianfranco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408637/
https://www.ncbi.nlm.nih.gov/pubmed/32645881
http://dx.doi.org/10.3390/cancers12071819
_version_ 1783567877210636288
author Bellenghi, Maria
Puglisi, Rossella
Pontecorvi, Giada
De Feo, Alessandra
Carè, Alessandra
Mattia, Gianfranco
author_facet Bellenghi, Maria
Puglisi, Rossella
Pontecorvi, Giada
De Feo, Alessandra
Carè, Alessandra
Mattia, Gianfranco
author_sort Bellenghi, Maria
collection PubMed
description Worldwide, the total incidence of cutaneous melanoma is higher in men than in women, with some differences related to ethnicity and age and, above all, sex and gender. Differences exist in respect to the anatomic localization of melanoma, in that it is more frequent on the trunk in men and on the lower limbs in women. A debated issue is if—and to what extent—melanoma development can be attributed to gender-specific behaviors or to biologically intrinsic differences. In the search for factors responsible for the divergences, a pivotal role of sex hormones has been observed, although conflicting results indicate the involvement of other mechanisms. The presence on the X chromosome of numerous miRNAs and coding genes playing immunological roles represents another important factor, whose relevance can be even increased by the incomplete X chromosome random inactivation. Considering the known advantages of the female immune system, a different cancer immune surveillance efficacy was suggested to explain some sex disparities. Indeed, the complexity of this picture emerged when the recently developed immunotherapies unexpectedly showed better improvements in men than in women. Altogether, these data support the necessity of further studies, which consider enrolling a balanced number of men and women in clinical trials to better understand the differences and obtain actual gender-equitable healthcare.
format Online
Article
Text
id pubmed-7408637
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74086372020-08-13 Sex and Gender Disparities in Melanoma Bellenghi, Maria Puglisi, Rossella Pontecorvi, Giada De Feo, Alessandra Carè, Alessandra Mattia, Gianfranco Cancers (Basel) Review Worldwide, the total incidence of cutaneous melanoma is higher in men than in women, with some differences related to ethnicity and age and, above all, sex and gender. Differences exist in respect to the anatomic localization of melanoma, in that it is more frequent on the trunk in men and on the lower limbs in women. A debated issue is if—and to what extent—melanoma development can be attributed to gender-specific behaviors or to biologically intrinsic differences. In the search for factors responsible for the divergences, a pivotal role of sex hormones has been observed, although conflicting results indicate the involvement of other mechanisms. The presence on the X chromosome of numerous miRNAs and coding genes playing immunological roles represents another important factor, whose relevance can be even increased by the incomplete X chromosome random inactivation. Considering the known advantages of the female immune system, a different cancer immune surveillance efficacy was suggested to explain some sex disparities. Indeed, the complexity of this picture emerged when the recently developed immunotherapies unexpectedly showed better improvements in men than in women. Altogether, these data support the necessity of further studies, which consider enrolling a balanced number of men and women in clinical trials to better understand the differences and obtain actual gender-equitable healthcare. MDPI 2020-07-07 /pmc/articles/PMC7408637/ /pubmed/32645881 http://dx.doi.org/10.3390/cancers12071819 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bellenghi, Maria
Puglisi, Rossella
Pontecorvi, Giada
De Feo, Alessandra
Carè, Alessandra
Mattia, Gianfranco
Sex and Gender Disparities in Melanoma
title Sex and Gender Disparities in Melanoma
title_full Sex and Gender Disparities in Melanoma
title_fullStr Sex and Gender Disparities in Melanoma
title_full_unstemmed Sex and Gender Disparities in Melanoma
title_short Sex and Gender Disparities in Melanoma
title_sort sex and gender disparities in melanoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408637/
https://www.ncbi.nlm.nih.gov/pubmed/32645881
http://dx.doi.org/10.3390/cancers12071819
work_keys_str_mv AT bellenghimaria sexandgenderdisparitiesinmelanoma
AT puglisirossella sexandgenderdisparitiesinmelanoma
AT pontecorvigiada sexandgenderdisparitiesinmelanoma
AT defeoalessandra sexandgenderdisparitiesinmelanoma
AT carealessandra sexandgenderdisparitiesinmelanoma
AT mattiagianfranco sexandgenderdisparitiesinmelanoma